Heron Therapeutics Inc (NASDAQ:HRTX) was the target of unusually large options trading activity on Wednesday. Traders bought 1,188 put options on the stock. This represents an increase of 1,700% compared to the typical volume of 66 put options.
Several large investors have recently bought and sold shares of HRTX. Meadow Creek Investment Management LLC acquired a new position in Heron Therapeutics during the second quarter valued at $27,000. Parallel Advisors LLC lifted its position in Heron Therapeutics by 247.4% during the first quarter. Parallel Advisors LLC now owns 1,685 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 1,200 shares during the period. Lindbrook Capital LLC acquired a new position in Heron Therapeutics during the second quarter valued at $37,000. US Bancorp DE lifted its position in Heron Therapeutics by 75.6% during the second quarter. US Bancorp DE now owns 4,108 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,769 shares during the period. Finally, Tiverton Asset Management LLC acquired a new position in Heron Therapeutics during the second quarter valued at $101,000.
Several equities research analysts have recently commented on HRTX shares. ValuEngine upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st. BidaskClub upgraded shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 10th. Stifel Nicolaus reiterated a “buy” rating and set a $38.00 price objective on shares of Heron Therapeutics in a research note on Monday, August 5th. Evercore ISI reiterated a “buy” rating and set a $75.00 price objective on shares of Heron Therapeutics in a research note on Tuesday, August 13th. Finally, Northland Securities reiterated a “buy” rating and set a $55.00 price objective on shares of Heron Therapeutics in a research note on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus price target of $52.67.
Shares of NASDAQ:HRTX remained flat at $$20.51 on Friday. 822,415 shares of the stock traded hands, compared to its average volume of 948,028. Heron Therapeutics has a 1-year low of $15.68 and a 1-year high of $35.10. The stock has a fifty day moving average price of $17.80 and a 200 day moving average price of $20.24. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.01 and a quick ratio of 3.70. The stock has a market cap of $1.64 billion, a price-to-earnings ratio of -8.41 and a beta of 1.47.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Monday, August 5th. The biotechnology company reported ($0.63) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.65) by $0.02. Heron Therapeutics had a negative net margin of 172.07% and a negative return on equity of 56.89%. The business had revenue of $36.66 million during the quarter, compared to the consensus estimate of $31.04 million. On average, sell-side analysts forecast that Heron Therapeutics will post -2.73 EPS for the current fiscal year.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Read More: Stocks Increasing Dividends
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.